Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 10/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466738 | 0.79 | MAPT (0.47) | ARFNTAFNTBCNR2MAPT | |
| SCHEMBL6467848 | 0.78 | AR (0.66) | ARMAPT | |
| SCHEMBL6466989 | 0.77 | AR (0.67) | ARMAPTLMNAKDM4E | |
| SCHEMBL6882430 | 0.74 | AR (0.75) | ARCNR2MAPTLMNASMN1; SMN2 | |
| SCHEMBL6466411 | 0.74 | AR (0.78) | ARMAPTLMNASMN1; SMN2KDM4E | |
| SCHEMBL6466975 | 0.73 | AR (0.49) | ARMAPTLMNASMN1; SMN2 | |
| SCHEMBL7046828 | 0.71 | AR (0.61) | ARLMNASMN1; SMN2 | |
| SCHEMBL6469678 | 0.70 | PTGDR2 (0.41) | ARMAPTSMN1; SMN2 | |
| SCHEMBL6469514 | 0.70 | AR (0.55) | ARMAPK14MAPTLMNAKDM4E | |
| SCHEMBL15998944 | 0.69 | TSHR (0.60) | MAPK14MAPTLMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | KCNK3 3824/4885AR 6/4885FNTA 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.